Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company pioneering precision oncology solutions through innovative target discovery and therapeutic development. This page provides authorized updates on their research programs, clinical trials, and strategic initiatives in cancer treatment innovation.
Investors and researchers will find verified information about TNGX's pipeline progress, including PRMT5 inhibitor developments for CNS/non-CNS cancers and discontinued programs like TNG348. All content undergoes strict verification to ensure accuracy in reporting scientific milestones and regulatory updates.
Key coverage areas include clinical trial phases, research collaborations, peer-reviewed study publications, and corporate developments. The resource is particularly valuable for tracking therapies addressing tumor suppressor gene restoration and immune evasion mechanisms.
Bookmark this page for real-time updates on Tango Therapeutics' work in CRISPR-enabled drug discovery and their mission to transform cancer treatment paradigms through precision medicine approaches.
Tango Therapeutics (NASDAQ: TNGX) showcased key findings from its precision oncology portfolio at the AACR 2023 Annual Meeting in Orlando, Florida. Presentations included promising preclinical data for TNG908, a PRMT5 inhibitor targeting glioblastoma, which is currently in a phase 1/2 clinical trial. Additionally, TNG260 showed potential in reversing immune evasion in STK11-mutant cancers and will enter clinical trials later in 2023. The company also highlighted TNG462, another promising PRMT5 inhibitor, and TNG348, a selective USP1 inhibitor for BRCA1/2 mutant cancers, with IND submissions planned. These developments underscore Tango's commitment to targeting critical cancer pathways.
Tango Therapeutics (NASDAQ: TNGX) has received FDA clearance for its IND application for TNG260, a first-in-class inhibitor targeting the CoREST complex, aimed at treating STK11-mutant cancers. This milestone enables the initiation of a Phase 1/2 clinical trial expected in the second half of 2023. STK11 mutations contribute to resistance against standard immunotherapies in cancers such as non-small cell lung cancer. The trial will assess the safety and efficacy of TNG260 in combination with pembrolizumab in patients with various solid tumors having STK11 mutations. This breakthrough underscores Tango's commitment to advancing precision cancer therapies.
Tango Therapeutics (NASDAQ: TNGX) announced key developments in its clinical pipeline and financial results for 2022. The FDA granted Fast Track Designation to TNG462, a next-generation PRMT5 inhibitor, following IND clearance in January 2023. The company initiated a clinical trial for TNG908 and expects updates on its progress in Q2 2023. Financially, Tango reported a net loss of $108.2 million for 2022, compared to $58.2 million in 2021. Collaboration revenue decreased to $24.9 million, down from $26.0 million. Research and development expenses rose to $105.9 million, reflecting increased program advancement costs. Tango ended 2022 with $366.1 million in cash, sufficient to fund operations until 2025.
Tango Therapeutics (NASDAQ: TNGX) announced the acceptance of two oral and two poster presentations at the AACR 2023 Annual Meeting from April 14-19 in Orlando, Florida. The oral presentations include TNG908, a promising PRMT5 inhibitor showing three-fold increased median survival in glioblastoma models, and TNG260, aimed at STK11-mutant cancers. The poster presentations feature TNG348, targeting BRCA1/2 mutations, and TNG462, another PRMT5 inhibitor for MTAP-deleted tumors. These findings highlight Tango's innovative approach in precision oncology and the potential for advancements in cancer treatment.
Tango Therapeutics (NASDAQ: TNGX) announced on March 10, 2023, that it is monitoring the situation involving Silicon Valley Bank (SVB) and expects no impact on its financial guidance. The company has sufficient cash, equivalents, and marketable securities to support operations through 2025.
Tango Therapeutics focuses on developing precision cancer medicines based on synthetic lethality. The company is dedicated to identifying new drug targets and advancing therapies that effectively address critical cancer mechanisms.
Tango Therapeutics (NASDAQ: TNGX) announced the grant of non-qualified stock options and restricted stock units (RSUs) totaling 637,000 shares and 106,250 RSUs, respectively, to two new employees as part of its 2023 Inducement Plan. This includes 487,500 stock options and 81,250 RSUs awarded to Adam Crystal, M.D., Ph.D., following his appointment as President of Research and Development. The options have an exercise price of $5.20 per share, aligning with the stock's closing price on the grant date, March 1, 2023. The vesting schedules for both options and RSUs are contingent upon continued employment.
Tango Therapeutics (NASDAQ: TNGX), a biotechnology company focused on advanced cancer treatments, announced key investor conference appearances in March 2023. CEO Barbara Weber will participate in the Cowen 43rd Annual Health Care Conference on March 8 at 11:10 AM ET in Boston, and the Barclays Global Healthcare Conference on March 14 at 3:35 PM ET in Miami. Live webcasts of these presentations will be accessible on their website, with replays available for 90 days post-event. Tango Therapeutics aims to leverage synthetic lethality to develop innovative cancer therapies targeting tumor suppressor gene loss.
Tango Therapeutics, a clinical-stage biotechnology firm (NASDAQ: TNGX), has appointed Adam Crystal, M.D., Ph.D. as President of Research and Development. Dr. Crystal will lead preclinical research, drug discovery, and clinical development, working with existing leaders in the company. Tango is currently enrolling patients in a crucial clinical trial and plans to introduce three more programs in the next year. Dr. Crystal's expertise in precision oncology is expected to enhance the advancement of Tango's pipeline, which focuses on synthetic lethal targeting in cancer treatment.
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicine, is set to participate in key investor conferences this February. The first event is the Guggenheim Healthcare Talks | 2023 Oncology Conference on February 9, 2023, at 1:00 PM ET in New York. The second is the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET, conducted virtually. Live webcasts will be available on the Company's website, with replays archived post-presentation. Tango is committed to advancing cancer treatment through innovative drug targets and leveraging synthetic lethality principles.
Tango Therapeutics (NASDAQ: TNGX) recently announced significant developments in its clinical pipeline. The U.S. FDA has granted Orphan Drug Designation to TNG908 for treating malignant glioma, enhancing its market exclusivity and providing potential financial incentives. Additionally, the FDA cleared an Investigational New Drug (IND) application for TNG462, a next-generation inhibitor targeting MTAP-deleted cancers, with a clinical trial expected to start in mid-2023. These advancements may broaden the company's strategic options and opportunity to address unmet medical needs in oncology.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
